Sky Medical Technology Limited

Product: 
Technology Growth
Status: 
Closed
Sector: 
Medical Technology
Aim of funding: 
Growth
HMRC Advance Assurance received: 
Yes

Sky Medical Technology Limited

Description: 

Sky Medical Technology Limited has developed the OnPulse(TM) technology platform, a technology which, at its core, has been proven to dramatically improve blood flow (both volume and velocity) and elevates oxygen levels in the blood. The results indicate that the platform can be used across a variety of indications, displacing both pharmaceutical and device solutions on the market today.

The OnPulse technology has been proven through clinical studies and has received regulatory approval for sales in the EU, United States, Canada and Australia.  In the UK, NICE guidance supports the use of the gekoTM device for use within the NHS and the device is available commercially.

The predominant applications for the technology are:

  • Prevention and treatment of Deep Vein Thrombosis (DVT)
  • Surgical recovery
  • Chronic woundcare (‘hard to heal’ wounds)
  • Elite sports recovery

Additional opportunities for future development include treatment in the areas of urinary incontinence, accelerated bone union, cardiac support, enhanced drug delivery and equine care.

 

Opportunity: 

The market opportunity within the DVT market is substantial. The anti-thrombotic drug market was over $14.6 billion in 2004[1], with market estimates of the DVT device market at over $1.6 billion[2] (North America, EU, Japan). Over 600,000 people suffer from DVT in the United States alone annually, resulting in up to 200,000 deaths annually from Pulmonary Embolism[3]. Current market treatments include anti-coagulant drugs, pneumatic compression devices, and compression hosiery; however, no current treatment meets market demands for high performance, comfort and ease of use. Sky Medical believes its technology meets these needs in a novel and disruptive way. The reported occurrence of DVT varies widely, from 250,000 cases per year up to 20,000,000 in the United States alone[4]. The American Public Health Association estimates that up to 600,000 Americans will suffer from DVT each year[5]. It is further estimated that up to 200,000 pulmonary embolism (PE) deaths will occur from the DVT2. More people will die each year in the United States from pulmonary embolisms resulting from DVT than from AIDS, breast cancer and automobile accidents combined[2]. The estimates for the EU are similar on both counts of those affected by DVT and those that die as a result.

In addition to the DVT market, Sky Medical also estimates the Hard to Heal Wounds market to be worth C.$20bn in the US and C.£2bn in the UK. In addition, Sky estimates the surgical recovery market to be worth around £1.8bn annually.

The elite sport recovery market is a much smaller market but provides high-impact news opportunities and is a useful brand positioning tool. The likes of Team GB, British Cycling, San Francisco 49ers, AC Milan, Chelsea and the USA Olympic team all use the technology as part of their recovery treatment. 

We envisage an exit for our investors via a sale to one of the Company’s partners or an IPO trade sale, targeting  a return of around 4-5x capital invested.

 

 

1. Delphi Pharma, Market Trend Data Base (Pg 35 http://goo.gl/OiGuK )

2. Frost & Sullivan, US & European Compression Therapy Market Reports 2009

3. US Surgeon General, “Call to Action” report issued August 2008

4. Gary P Siskin, MD, Associate Professor, Department of Radiology, Albany Medical ; Chief, Division of Vascular and Interventional Radiology, Department of Radiology, Albany Medical Center (www.emedicine.com/Radio/topic762.htm)

5. American Public Health Association. Deep Vein Thrombosis: Advancing Awareness to Protect Patient Lives. February 26, 2003

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.